Deep Brain Stimulation Therapy and Intestinal Microbiota

April 21, 2021 updated by: The First Affiliated Hospital with Nanjing Medical University

Effect of Deep Brain Stimulation Therapy on Intestinal Microbiota in Patients With Parkinson's Disease

This study aims to observe the changes of intestinal microbiota after deep brain stimulation (DBS) therapy for Parkinson's disease, and explore the role of intestinal microbiota in the neuroprotective effect of DBS.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Recruiting

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Observational

Enrollment (Anticipated)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
30

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.

Study Locations

  • China
    • Jiangsu
      • Nanjing, Jiangsu, China, 210029
        • Recruiting
        • the Hospital Research Ethics Committee of the First Affiliated Hospital of Nanjing Medical University
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

18 years to 80 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

Patients with Parkinson's disease and are expected to undergo DBS therapy

Description

Inclusion Criteria:

  1. > 18 years of age;
  2. Primary Parkinson's disease diagnosed according to British Brain Bank criteria (Hoehn and Yahr);
  3. Deep brain stimulator therapy;
  4. Sign the informed consent.

Exclusion Criteria:

  1. Use of probiotics or probiotics during the study;
  2. Use antibiotics against intestinal bacteria at present or within the last 1 month;
  3. With cognitive dysfunction or mental illness;
  4. With severe diseases or is not expected to survive for more than a year;
  5. A history of gastrointestinal surgery;
  6. AIDS patients, hepatitis B/C positive.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Change in gut microbiota
Time Frame: Baseline (Before deep brain stimulation therapy)/3 month after deep brain stimulation therapy
Analyzed by 16sRNA sequencing of feces
Baseline (Before deep brain stimulation therapy)/3 month after deep brain stimulation therapy
Change in gut microbiota
Time Frame: Baseline (Before deep brain stimulation therapy)/6 month after deep brain stimulation therapy
Analyzed by 16sRNA sequencing of feces
Baseline (Before deep brain stimulation therapy)/6 month after deep brain stimulation therapy

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Change in blood biomarkers of neuroinflammation and alpha-synuclein
Time Frame: Baseline (Before deep brain stimulation therapy)/3 month after deep brain stimulation therapy
Comparing the changes of blood biomarkers such as neuroinflammation (TNF-alpha, IL-6, LPS) and alpha-synuclein
Baseline (Before deep brain stimulation therapy)/3 month after deep brain stimulation therapy
Change in blood biomarkers of neuroinflammation and alpha-synuclein
Time Frame: Baseline (Before deep brain stimulation therapy)/6 month after deep brain stimulation therapy
Comparing the changes of blood biomarkers such as neuroinflammation (TNF-alpha, IL-6, LPS) and alpha-synuclein
Baseline (Before deep brain stimulation therapy)/6 month after deep brain stimulation therapy
Frequency of defecation
Time Frame: Baseline (Before deep brain stimulation therapy)/3 month after deep brain stimulation therapy
Baseline (Before deep brain stimulation therapy)/3 month after deep brain stimulation therapy
Frequency of defecation
Time Frame: Baseline (Before deep brain stimulation therapy)/6 month after deep brain stimulation therapy
Baseline (Before deep brain stimulation therapy)/6 month after deep brain stimulation therapy
Dosage of anti-Parkinson's agent
Time Frame: Baseline (Before deep brain stimulation therapy)/3 month after deep brain stimulation therapy
Baseline (Before deep brain stimulation therapy)/3 month after deep brain stimulation therapy
Dosage of anti-Parkinson's agent
Time Frame: Baseline (Before deep brain stimulation therapy)/6 month after deep brain stimulation therapy
Baseline (Before deep brain stimulation therapy)/6 month after deep brain stimulation therapy
Change in the score of Unified Parkinson's Disease Rating Scales
Time Frame: Baseline (Before deep brain stimulation therapy)/3 month after deep brain stimulation therapy
It is consisted of six scales, each scale is graded on a scale of 5 (0-4), with zero being normal and 4 being severe.
Baseline (Before deep brain stimulation therapy)/3 month after deep brain stimulation therapy
Change in the score of Unified Parkinson's Disease Rating Scales
Time Frame: Baseline (Before deep brain stimulation therapy)/6 month after deep brain stimulation therapy
It is consisted of six scales, each scale is graded on a scale of 5 (0-4), with zero being normal and 4 being severe.
Baseline (Before deep brain stimulation therapy)/6 month after deep brain stimulation therapy
Parkinson's Disease Quality of Life Questionnaire-39 (PDQ-39)
Time Frame: Baseline (Before deep brain stimulation therapy)/3 month after deep brain stimulation therapy
Change in PDQ-39 scores, higher scores mean a worse outcome
Baseline (Before deep brain stimulation therapy)/3 month after deep brain stimulation therapy
Parkinson's Disease Quality of Life Questionnaire-39 (PDQ-39)
Time Frame: Baseline (Before deep brain stimulation therapy)/6 month after deep brain stimulation therapy
Change in PDQ-39 scores, higher scores mean a worse outcome
Baseline (Before deep brain stimulation therapy)/6 month after deep brain stimulation therapy

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
The First Affiliated Hospital with Nanjing Medical University

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Study Chair: Cunming Liu, The First Affiliated Hospital with Nanjing Medical University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Anticipated)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
April 15, 2021

Primary Completion (Anticipated)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
December 31, 2022

Study Completion (Anticipated)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
December 31, 2022

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
April 14, 2021

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
April 21, 2021

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
April 22, 2021

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
April 22, 2021

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
April 21, 2021

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
April 1, 2021

More Information

Terms related to this study

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • Ling Zhou

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings